Giotrif

Giotrif (Afatinib) is an oral medication used to treat specific types of non-small cell lung cancer. This targeted therapy works by blocking certain proteins that help cancer cells grow.

Giotrif is primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic markers. It targets epidermal growth factor receptor (EGFR) mutations, which are common in certain types of lung cancer. Patients often wonder, 'What is Giotrif used for?' It is designed to inhibit the growth and spread of cancer cells by interfering with the EGFR pathway.

Common effects of Giotrif may include skin rash, diarrhea, and fatigue. Some users also experience nausea, loss of appetite, and dry skin. These effects can vary in intensity and duration, depending on individual factors.

Giotrif should be handled with care, following the guidance of a healthcare professional. It is important to monitor for severe side effects and report any unusual symptoms. Patients with pre-existing conditions should discuss their medical history with their doctor before starting treatment.

Giotrif may interact with certain medications, including those that are metabolized by the liver's CYP3A4 enzyme. It is advisable to avoid grapefruit and grapefruit juice, as they can affect the metabolism of Afatinib. Always consult a healthcare provider before combining Giotrif with other medications.